Prostate specific membrane antigen binding protein
Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
1. An isolated single domain antibody that is capable of specifically binding to a PSMA polypeptide comprising SEQ ID No. 20, the single domain antibody comprising complementarity determining regions (CDRs) as follows: (i) a CDR1 comprising the sequence of SEQ ID No. 5, (ii) a CDR2 comprising the sequence of SEQ ID No. 17, and (iii) a CDR3 comprising the sequence of SEQ ID No. 15.
2. The isolated single domain antibody of claim 1 , wherein the single domain antibody has the amino acid sequence of SEQ ID No. 32.
3. The isolated single domain antibody of claim 2 , wherein said single domain antibody is part of a trispecific protein.
4. The isolated single domain antibody of claim 3 , wherein said trispecific protein has the amino acid sequence of SEQ ID No. 153.
5. An isolated polynucleotide encoding the single domain antibody according to claim 1 .
6. An isolated vector comprising the polynucleotide of claim 5 .
7. An isolated host cell transformed with the vector according to claim 6 .
8. A pharmaceutical composition comprising (i) a single domain antibody according to claim 1 , and (ii) a pharmaceutically acceptable carrier.